Ivabradine Aurovitas

Ivabradine, the active ingredient in Ivabradine Aurovitas, is a If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction, where it lowers heart rate without affecting contractility.

GNH USA supplies Ivabradine Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to manage conditions characterized by excessive heart rate.

Chronic stable angina pectoris: reduces the frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers resting heart rate to alleviate symptoms and support ventricular function. Patients intolerant to beta‑blockers: provides an alternative heart‑rate‑lowering strategy when beta‑blockade is not feasible.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Bradycardia: resting heart rate below 50 bpm. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache and dizziness. - Fatigue or general weakness. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other significant arrhythmias. - Severe hypotension leading to syncope. - Persistent visual impairment or retinal changes. - Hepatic enzyme elevation indicating possible liver injury.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor appropriately. - Cardiac conduction disease: avoid in patients with severe sinus node dysfunction or second‑degree AV block. - Resting heart rate: do not start if baseline HR is below 60 bpm. - Hepatic impairment: use with caution and consider dose adjustment. - Concomitant bradycardic agents: monitor for excessive heart‑rate reduction when combined with beta‑blockers or digoxin. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ivabradine can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase plasma levels. - Combined use with other bradycardic agents (beta‑blockers, digoxin): may cause excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may raise concentrations modestly. - Drugs that prolong QT interval: increase risk of arrhythmias. - Antihypertensives: additive blood‑pressure‑lowering effect requiring BP monitoring.